News
6d
GlobalData on MSNFDA approves Biocon Biologics’ bevacizumab biosimilar for cancerJobevne is a recombinant humanised monoclonal antibody which functions as a vascular endothelial growth factor inhibitor ...
Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...
During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic ...
Biocon’s share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company’s seventh USFDA ...
Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNEâ„¢ (bevacizumab-nwgd), a ...
Biocon's stock price increased almost 4 per cent in the early trading session on 11 April after the company’s subsidiary ...
Epogen was named Fortune magazine’s ‘product of the year’ in 1989.1 Having set the stage for the company’s continued growth ... colony-stimulating factor), that could be used to treat ...
Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...
The global cancer supportive care products market is set to experience steady growth, with an estimated market value of USD 20.63 billion in 2022. According to industry forecasts, this market is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results